Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

US Patent 9827198 · Granted Nov 28, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-y2024
Solid, orally administrable pharmaceutical composition2016
Process for the preparation of a solid, orally administrable pharmaceutical comp2016
N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (M2015
Solid orally administerable pharmaceutical dosage forms with rapid active princi2013
Pharmaceutical dosage forms comprising an active ingredient combination of nifed2012
Crystalline potassium salt of lipoxin A4 analogs2011
N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (M2011
Crystalline forms of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-2011
Crystalline potassium salt of lipoxin A4 analogs2011
Solid body forms of mesoprogestin 11β-{4E-(hydroxyiminomethyl)-phenyl}-17α metho2010
Flavor-masked pharmaceutical compositions2000